Clinical Trial Update: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority [Phase 3]

View source ↗

Summary

Phase 3 trial investigating anticoagulants for rheumatic heart disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatic Heart Disease

Drugs mentioned

• Aspirin (Aspirin)
• Rivaroxaban (rivaroxaban)
• Vitamin K antagonists

Snippet

Sponsor: Population Health Research Institute | Conditions: Rheumatic Heart Disease | Phase 3 | Status: WITHDRAWN